By Michael Kim
READ THE FULL CCLD RESEARCH REPORT
Pre-market open on 8/5/25, CareCloud (NASDAQ:CCLD) reported 2Q25 earnings results. For the quarter, CCLD reported GAAP net income of $2.9 million – the company’s fifth consecutive positive net income quarter, and up from $1.7 million for the year-ago quarter. After taking into consideration preferred stock dividends, the company reported net income attributable to common shareholders of $1.5 million, or $0.04 per share, for 2Q25 – CCLD’s first profitable quarter inclusive of preferred stock dividend payments, and a reversal from a net loss of $2.2 million, or ($0.14) per share, for 2Q24. Much of the year-over-year variance can be attributed to more favorable operating and non-operating income trends, combined with meaningfully lower preferred stock dividends.
Excluding stock-based compensation expense, amortization of purchased intangible assets, other (income)/expense, transaction and integration costs, as well as preferred stock dividends, Adjusted EPS totaled $0.08 based on our calculations, or right in line with our estimate. Relative to our model, modestly lower expenses were about offset by a slight revenue shortfall.
On a GAAP basis, our updated model calls net income attributable to common shareholders of $0.12 per share for 2025 (within management’s reiterated $0.10 to $0.13 guidance range) followed by $0.26 per share in 2026. Excluding stock-based compensation expense, amortization of purchased intangible assets, other (income)/expense, integration costs, transaction costs, goodwill impairment charges, changes in contingent considerations, and related tax impacts, as well as preferred stock dividends, we forecast Adjusted EPS of $0.30 for 2025 and $0.41 for 2026 (up from our prior $0.40 estimate). Our slightly higher 2026 outlook primarily reflects a steeper margin expansion trajectory, as management increasingly leverages AI to drive operating efficiencies. Focusing on the top line, we forecast total revenues of $111.0 million in 2025 (consistent with management’s unchanged guidance range of $111 million to $114 million), followed by $126.7 million in 2026, as business development initiatives increasingly take hold and management captures incremental economics from existing customers via complementary services. Furthermore, senior executives reiterated 2025 Adjusted EBITDA guidance of $26 million to $28 million.
Turning to valuation, no change to $5.00 DCF-derived price target, representing meaningful upside potential from current levels. Despite the stock’s more recent outperformance, we continue to look for an upward revaluation for shares of CCLD, as awareness and appreciation of the company’s unique business model, durable competitive advantages, and reaccelerating growth prospects compound. Moreover, comparable Healthcare Information Services small cap stocks continue to trade at meaningfully higher Price-to-Earnings multiples across the board, thereby reinforcing our valuation work.
We highlight the following key takeaways from 2Q25 results:
1. Transitioning Artificial Intelligence strategy from planning to production: As discussed at length in prior conference calls, as well as our recent CEO Fireside Chat (http://scr.zacks.com/news/news-details/2025/Fireside-Chat-with-Stephen-Snyder-and-Hadi-Chaudhry-Co-Chief-Executive-Officers-of-CareCloud-Inc-), senior officials remain focused on transforming the broader healthcare journey by increasingly deploying innovative and proven AI solutions. More specifically, CCLD’s “AI Center of Excellence” is now fully operational, with 100 full-time employees (FTEs) onboard, along with 100 interns (with some likely transitioning to full-time roles). Looking ahead, the goal remains to employ 500 related FTEs by year-end, with incremental expenses likely manageable given a meaningful portion of related compensation costs can be capitalized on the balance sheet.
By leveraging 25 years of proprietary data (processing 10 million claims/transactions per month + volumes of clinical data) to train/iterate models, senior executives are incorporating proprietary AI solutions across operations, products, and services to enhance provider/patient experience, streamline claims coding, improve A/R workflows, and augment denial management efficacy. Initial AI applications include cirrusAI Notes (documentation assistant) and cirrusAI Voice (call center monitoring/evaluation platform), with plans to introduce AI-enabled Front Desk Agent and Personal Health Record (PHR) capabilities to handle inbound calls and automate appointment scheduling, prescription refills, and lab results updates, with voice assistants conducting pre-visit interviews and pre-populating notes. Stepping back, key AI benefits include incremental top-line contributions from new products/services, enhancing customer satisfaction and retention reflecting more competitive/differentiated capabilities, and rising margins/profitability via back-office optimization/operational efficiencies.
2. Expanding footprint to drive sustainable growth: In addition to targeting more specialized practices (see CCLD’s recently launched dermatology-focused Electronic Health Records business), the company’s EHR platform recently attained ONC Health IT Certification for Critical Access Hospitals (CAHs). We view the certification as a key catalyst for CCLD to increasingly penetrate a $1.5+ billion addressable market spanning more than 1,300 CAHs across rural markets needing to upgrade legacy EHR systems. More specifically, CCLD’s cloud-based, AI-enabled capabilities can materially enhance A/R processes while integrating RCM services.
3. Rising free cash flow story: In the first half of this year, CCLD generated $9.1 million of free cash flow, up from $4.9 million in 1H24. Looking ahead, our model calls for continued growth reflecting rising revenues and ongoing margin expansion. To be sure, expenses continue to trend lower, with senior officials remaining committed to driving operational efficiencies and productivity gains.
In light of CCLD’s disciplined execution, rising operating leverage, and improving financial performance (as reinforced by the positive GAAP net income inflection in 2Q25), the company maintains ample capacity to continue to reinvest for growth and capitalize on incremental M&A opportunities. Indeed, cash on the balance sheet continues to build, with $10.4 million as of June 30, 2025, up from $2.6 million a year ago. Moreover, the recent conversion of Series A Preferred Stock to common stock reduces annual dividend payments by ~$7.7 million. Finally, management can tap the company’s $10 million credit facility as needed.
4. Building M&A pipeline: Management remains focused on acquiring sub-scale RCM providers at financially attractive terms. The M&A pipeline remains strong, particularly as it relates to non-core/distressed assets that bring clients/relationships at low Customer Acquisition Costs (CACs), as well as synergistic opportunities. While senior executives remain disciplined on pricing and strategic fit, management increasingly views M&A as an attractive path to enter new markets and drive incremental growth via cross-selling services and leveraging existing infrastructure/technology post-acquisition.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
